GLP-1RA have shown to control HbA1C levels in patients with T2DM alongside alleviating the frequently existing comorbids, HTN and dyslipidaemia in combination with SGLT2 inhibitors (115). This evidence concerns the gene SLC5A2 and hypertensive disorder.